{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:44Z","timestamp":1753868684292,"version":"3.41.2"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>L\u2010asparaginase is an important component of acute lymphoblastic leukemia (ALL) treatment. However, it is associated with an increased risk of thrombosis which in turn increases the risk of morbidity and mortality and also poses a negative effect on leukemia\u2010related outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the prevalence of thrombotic events and their associated factors in patients with ALL treated with L\u2010asparaginase\u2010containing regimens in Tikur Anbessa Specialized Hospital (TASH) from November 2020 to November 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010center retrospective cross\u2010sectional study was conducted at TASH. A total of 152 ALL patients who have been treated or were on treatment with L\u2010asparaginase\u2010containing regimens from November 2020 to November 2023 were included in the study. Data were collected from the patient's medical records. Data were entered and analyzed with SPSS version 26, and a chi\u2010square test was used to assess the association of independent variables with the dependent variable. Bivariate and multivariate logistic regression analyses were used to determine the presence of significant correlation between dependent and independent variables and those with <jats:italic>p<\/jats:italic>\u2010value of 0.25 were included in the multivariate analysis. For multivariate analysis a <jats:italic>p<\/jats:italic>\u2010value\u2009&lt;\u20090.05 was considered as statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the participants was 22.5\u2009years (IQR 18, 30.8), and 59.9% of them were male. The majority (84.2%) of patients were treated with pediatric\u2010inspired ALL CALGB10403 protocol. Eleven point two percent of the patients developed a documented thrombotic event. All of the events were venous and, cerebral venous thrombosis was the most common site (41.2%). Thrombosis occurred during remission induction in 44.4%. On multivariate logistic regression analysis, age\u2009\u2265\u200940\u2009years and longer time to achieve complete remission (CR) of\u2009&gt;\u20094\u2009weeks (Age\u2009\u2265\u200940\u2009years, <jats:italic>p<\/jats:italic>\u2009=\u20090.019; adjusted odds ratio [AOR] 10.4, 95% confidence interval [CI]\u2009=\u20091.47\u201375.0 and, time to achieve CR\u2009&gt;\u200904\u2009weeks <jats:italic>p<\/jats:italic>\u2009=\u20090.037; AOR 4.8, 95% CI\u2009=\u20091.10\u201320.72) were significantly associated with increased risk of thrombosis. Patients who developed thrombosis had a statistically non\u2010significant higher rate of mortality compared with those without thrombosis (47% vs. 41.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.618). Around a third (29.4%) of the deaths in the patients with thrombosis were direct effects of the thrombotic event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study showed that the risk of L\u2010asparaginase\u2010associated thrombosis in resource\u2010limited settings like ours is comparable with previous reports from other parts of the world, but the mortality directly attributed to thrombosis is remarkably higher. Older age above 40\u2009years and longer time to achieve CR are independent predictors of higher thrombosis risk. Future prospective studies need to look into the contributing factors, and preventive and treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.70153","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:15:53Z","timestamp":1741619753000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Risk Factors of L\u2010Asparaginase\u2010Related Thrombosis Among Acute Lymphoblastic Lymphoma Patients in a Resource\u2010Limited Setup of Sub\u2010Saharan Region"],"prefix":"10.1002","volume":"8","author":[{"given":"Amira","family":"Abrar Mohammed","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences Addis Ababa University  Addis Ababa Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fozia","family":"Abdela","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences Addis Ababa University  Addis Ababa Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6923-1753","authenticated-orcid":false,"given":"Abel Tenaw","family":"Tasamma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences Addis Ababa University  Addis Ababa Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yemisrach Kifle","family":"Shewangizaw","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences Addis Ababa University  Addis Ababa Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahlet Tsige","family":"Weldeamanuel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences Addis Ababa University  Addis Ababa Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.09.010"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.1003056"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.184769"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100908"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231084"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02383.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-11-0845"},{"issue":"8","key":"e_1_2_11_12_1","first-page":"235","article-title":"Trend to Efficacy and Safety Using Antithrombin Concentrate in Prevention of Thrombosis in Children Receiving l\u2010Asparaginase for Acute Lymphoblastic Leukemia","volume":"90","author":"Mitchell L.","year":"2003","journal-title":"Results of the PARKAA Study"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12948"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12600"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2020-0009"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015511"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00032.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24130"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06677.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13636"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04252-y"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29581"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194175"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:24:06Z","timestamp":1748363046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cnr2.70153"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70153","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70153"}}